Recombinant	0	11	O
human	12	17	B-Organism
prothrombin	18	29	B-Gene_or_gene_product
kringle	30	37	I-Gene_or_gene_product
-	37	38	I-Gene_or_gene_product
2	38	39	I-Gene_or_gene_product
inhibits	40	48	O
B16F10	49	55	B-Pathological_formation
melanoma	56	64	I-Pathological_formation
metastasis	65	75	O
through	76	83	O
inhibition	84	94	O
of	95	97	O
neovascularization	98	116	O
and	117	120	O
reduction	121	130	O
of	131	133	O
matrix	134	140	B-Gene_or_gene_product
metalloproteinase	141	158	I-Gene_or_gene_product
expression	159	169	O
.	169	170	O

Angiogenesis	172	184	O
,	184	185	O
a	186	187	O
multi	188	193	O
-	193	194	O
step	194	198	O
process	199	206	O
which	207	212	O
involves	213	221	O
endothelial	222	233	B-Cell
cell	234	238	I-Cell
proliferation	239	252	O
,	252	253	O
adhesion	254	262	O
,	262	263	O
migration	264	273	O
,	273	274	O
and	275	278	O
basement	279	287	B-Cellular_component
membrane	288	296	I-Cellular_component
(	297	298	O
BM	298	300	B-Cellular_component
)	300	301	O
degradation	302	313	O
,	313	314	O
is	315	317	O
essential	318	327	O
for	328	331	O
tumor	332	337	B-Pathological_formation
metastasis	338	348	O
.	348	349	O

Here	350	354	O
we	355	357	O
show	358	362	O
that	363	367	O
recombinant	368	379	O
human	380	385	B-Organism
prothrombin	386	397	B-Gene_or_gene_product
kringle	398	405	I-Gene_or_gene_product
-	405	406	I-Gene_or_gene_product
2	406	407	I-Gene_or_gene_product
(	408	409	O
rk	409	411	B-Gene_or_gene_product
-	411	412	I-Gene_or_gene_product
2	412	413	I-Gene_or_gene_product
)	413	414	O
inhibited	415	424	O
bovine	425	431	B-Organism
capillary	432	441	B-Cell
endothelial	442	453	I-Cell
cell	454	458	I-Cell
migration	459	468	O
with	469	473	O
an	474	476	O
IC	477	479	O
(	479	480	O
50	480	482	O
)	482	483	O
(	484	485	O
concentration	485	498	O
for	499	502	O
half	503	507	O
maximal	508	515	O
inhibition	516	526	O
)	526	527	O
of	528	530	O
38	531	533	O
nM	534	536	O
and	537	540	O
inhibited	541	550	O
adhesion	551	559	O
to	560	562	O
extracellular	563	576	B-Cellular_component
matrix	577	583	I-Cellular_component
(	584	585	O
ECM	585	588	B-Cellular_component
)	588	589	O
proteins	590	598	O
.	598	599	O

Because	600	607	O
tumor	608	613	B-Pathological_formation
metastasis	614	624	O
requires	625	633	O
angiogenesis	634	646	O
,	646	647	O
we	648	650	O
examined	651	659	O
whether	660	667	O
rk	668	670	B-Gene_or_gene_product
-	670	671	I-Gene_or_gene_product
2	671	672	I-Gene_or_gene_product
could	673	678	O
inhibit	679	686	O
metastases	687	697	B-Pathological_formation
induced	698	705	O
by	706	708	O
injection	709	718	O
of	719	721	O
B16F10	722	728	B-Cell
melanoma	729	737	I-Cell
cells	738	743	I-Cell
into	744	748	O
mice	749	753	B-Organism
.	753	754	O

The	755	758	O
results	759	766	O
revealed	767	775	O
that	776	780	O
the	781	784	O
metastatic	785	795	O
tumors	796	802	B-Pathological_formation
in	803	805	O
mouse	806	811	B-Organism
lung	812	816	B-Organ
were	817	821	O
markedly	822	830	O
decreased	831	840	O
in	841	843	O
a	844	845	O
dose	846	850	O
-	850	851	O
dependent	851	860	O
manner	861	867	O
and	868	871	O
acute	872	877	O
lung	878	882	B-Organ
injury	883	889	O
induced	890	897	O
by	898	900	O
B16F10	901	907	B-Pathological_formation
melanoma	908	916	I-Pathological_formation
metastasis	917	927	O
was	928	931	O
diminished	932	942	O
by	943	945	O
systemic	946	954	O
rk	955	957	B-Gene_or_gene_product
-	957	958	I-Gene_or_gene_product
2	958	959	I-Gene_or_gene_product
treatment	960	969	O
.	969	970	O

In	971	973	O
immunohistochemical	974	993	O
analysis	994	1002	O
,	1002	1003	O
rk	1004	1006	B-Gene_or_gene_product
-	1006	1007	I-Gene_or_gene_product
2	1007	1008	I-Gene_or_gene_product
reduced	1009	1016	O
expression	1017	1027	O
of	1028	1030	O
vascular	1031	1039	B-Gene_or_gene_product
endothelial	1040	1051	I-Gene_or_gene_product
growth	1052	1058	I-Gene_or_gene_product
factor	1059	1065	I-Gene_or_gene_product
,	1065	1066	O
which	1067	1072	O
is	1073	1075	O
a	1076	1077	O
potent	1078	1084	O
angiogenic	1085	1095	O
activator	1096	1105	O
and	1106	1109	O
neovascularization	1110	1128	O
in	1129	1131	O
the	1132	1135	O
mouse	1136	1141	B-Organism
lung	1142	1146	B-Organ
.	1146	1147	O

Also	1148	1152	O
,	1152	1153	O
rk	1154	1156	B-Gene_or_gene_product
-	1156	1157	I-Gene_or_gene_product
2	1157	1158	I-Gene_or_gene_product
diminished	1159	1169	O
the	1170	1173	O
expression	1174	1184	O
of	1185	1187	O
matrix	1188	1194	B-Gene_or_gene_product
metalloproteinase	1195	1212	I-Gene_or_gene_product
-	1212	1213	I-Gene_or_gene_product
2	1213	1214	I-Gene_or_gene_product
and	1215	1218	O
-	1219	1220	B-Gene_or_gene_product
9	1220	1221	I-Gene_or_gene_product
in	1222	1224	O
the	1225	1228	O
mouse	1229	1234	B-Organism
lung	1235	1239	B-Organ
which	1240	1245	O
induces	1246	1253	O
tumor	1254	1259	B-Pathological_formation
metastasis	1260	1270	O
and	1271	1274	O
angiogenesis	1275	1287	O
.	1287	1288	O

These	1289	1294	O
data	1295	1299	O
suggest	1300	1307	O
that	1308	1312	O
inhibition	1313	1323	O
of	1324	1326	O
B16F10	1327	1333	B-Pathological_formation
melanoma	1334	1342	I-Pathological_formation
metastasis	1343	1353	O
by	1354	1356	O
rk	1357	1359	B-Gene_or_gene_product
-	1359	1360	I-Gene_or_gene_product
2	1360	1361	I-Gene_or_gene_product
was	1362	1365	O
caused	1366	1372	O
by	1373	1375	O
inhibition	1376	1386	O
of	1387	1389	O
neovascularization	1390	1408	O
and	1409	1412	O
reduction	1413	1422	O
of	1423	1425	O
matrix	1426	1432	B-Gene_or_gene_product
metalloproteinase	1433	1450	I-Gene_or_gene_product
expression	1451	1461	O
.	1461	1462	O

